Adamis Pharmaceuticals Corporation

First quarter 2022 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Mr. Robert Ewell with ICR Westwick. Please go ahead.

Thank you, Operator. Good afternoon, everyone, and welcome to the Atomos Pharmaceuticals First Quarter 2022 Financial Results and Corporate Update Conference Call. Thank you for joining us today for the update, and welcome to our shareholders, analysts, and anyone interested in Atomos. Joining me today is Atomos' President and CEO, Dr. Dennis J. Carlo, Chief Medical Officer, Dr. Ron Moss, Chief Business Officer, David Margulio, and Chief Financial Officer, David Bendicto. The format for this call will consist of prepared remarks from management followed by Q&A. This call is being webcast and will be available for replay in the Investors section of our website, AtomosPharmaceuticals.com. In today's call, we will make certain forward-looking statements regarding our business based on current expectations and current information. Those statements speak only as of today, and except as required by law, we do not assume any duty to update in the future any forward-looking statement made today. Of course, any forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements that we make today. Additional information concerning factors that could affect our business and financial results is included in our most recent annual report on Form 10-K with the Securities and Exchange Commission and in other subsequent filings that we make with the SEC. These are available at the SEC's website. With that, I will now hand the call over to Dr. Dennis Carlo, President and CEO.

Thank you, Robert, and thanks to all of you for joining us today. It's not been that long since our last call, so today's call will be brief, but I will attempt to highlight a few important advancements. First, I'll begin with Zimhi, our naloxone product. Drug overdoses took more lives than ever before in 2021. Approximately 108,000 people died of drug overdoses, according to the CDC, two-thirds of these involving fentanyl. Drug overdose remains a significant problem that affects all sectors of our society. As we updated you on our last call, our commercial partner, U.S. World Meds, launched ZimHi at the end of March. In a few minutes, David Margulio will provide more information, but we are very pleased with the market reception of ZimHi and the update in both the retail and non-retail sectors of the market. U.S. World Meds has had some early wins among both commercial and government customers, and the next six months should reveal the sales trajectory we can expect for ZimHi. I'll now move on from Zemi to Symgepi. On March 21, 2022, Adams announced a voluntary recall of certain lots of Symgepi epinephrine injection, 0.15 milligrams and 0.3 milligrams, pre-filled single-dose syringes. Affected Symgepi product lots were recalled due to the potential clogging of the needle, preventing the dispensing of the drug product epinephrine. I'm happy to report that we believe that the investigation of the affected lots is nearing completion, that a root cause relating to a particular batch of syringe needles has been identified, and that corrective and preventive actions have been and will be taken. We anticipate a resolution and resumption of manufacturing after the investigation is completed and issues are satisfactorily addressed. We expect that this will occur in the near future. With that, I will turn it over to our CFO, David Benedicto, to provide some highlights from our recently filed financials. David.